Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model-Reference-Cited by-同舟云学术

Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model

Published:2017-03-02 Issue:4 Volume:15 Page:721-734
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Levin D.¹,Lagassé H. A. D.¹,Burch E.²,Strome S.²,Tan S.³,Jiang H.⁴,Sauna Z. E.¹,Golding B.⁵

Affiliation:

1. Hemostasis Branch; Division of Plasma Protein Therapeutics; Center for Biologics Evaluation and Research; Food and Drug Administration; Silver Spring MD USA

2. Department of Otorhinolaryngology-Head and Neck Surgery; University of Maryland School of Medicine; Baltimore MD USA

3. CRISPR Therapeutics; Cambridge MA USA

4. Editas Medicine; Cambridge MA USA

5. Plasma Derivatives Branch; Division of Plasma Protein Therapeutics; Center for Biologics Evaluation and Research; Food and Drug Administration; Silver Spring MD USA

Funder

U.S. Food and Drug Administration

Chief Scientist's Challenge Grant

Critical Path Initiative and a Cooperative Research and Development Agreement (CRADA)

Biogen

Office of Blood Research and Review

Center for Biologics Evaluation and Research

Publisher

Wiley

Subject

Hematology

Link